Captrust Financial Advisors Mirati Therapeutics, Inc. Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$39.16 - $88.71 $5,364 - $12,153	-137 Reduced 14.02%	840 $56,000
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $69,526 - $138,439	917 Added 1528.33%	977 $80,000
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $5,280 - $7,611	-40 Reduced 40.0%	60 $9,000
Q3 2021 Nov 16, 2021	BUY	$132.13 - $177.45 $7,531 - $10,114	57 Added 132.56%	100 $18,000
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $2,160 - $2,695	-15 Reduced 25.86%	43 $7,000

Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $1,271 - $1,772	8 Added 16.0%	58 $10,000
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $8,102 - $12,013	50 New	50 $11,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.